Cuscal Ltd
ASX:CCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cuscal Ltd
ASX:CCL
|
AU |
|
F
|
Fennec Pharmaceuticals Inc
TSX:FRX
|
US |
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
DK |
|
Secure Energy Services Inc
TSX:SES
|
CA |
|
Valeo Pharma Inc
TSX:VPH
|
CA |
|
O
|
Oak Street Health Inc
F:HE6
|
US |
|
Alpha Capital Acquisition Co
NASDAQ:ASPC
|
KY |
|
First Majestic Silver Corp
TSX:FR
|
CA |
|
ARS Pharmaceuticals Inc
NASDAQ:SPRY
|
US |
|
Finablr PLC
LSE:FIN
|
UK |
|
P
|
Patrangsit Healthcare Group PCL
SET:PHG
|
TH |
|
K
|
Kaman Corp
F:KA1
|
US |
Wall Street
Price Targets
CCL Price Targets Summary
Cuscal Ltd
According to Wall Street analysts, the average 1-year price target for CCL is 5.45 AUD with a low forecast of 5.15 AUD and a high forecast of 6.09 AUD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is CCL's stock price target?
Price Target
5.45
AUD
According to Wall Street analysts, the average 1-year price target for CCL is 5.45 AUD with a low forecast of 5.15 AUD and a high forecast of 6.09 AUD.
What is Cuscal Ltd's Revenue forecast?
Projected CAGR
-6%
For the last 2 years the compound annual growth rate for Cuscal Ltd's revenue is 13%. The projected CAGR for the next 3 years is -6%.
What is Cuscal Ltd's Operating Income forecast?
Projected CAGR
19%
For the last 2 years the compound annual growth rate for Cuscal Ltd's operating income is 14%. The projected CAGR for the next 3 years is 19%.
What is Cuscal Ltd's Net Income forecast?
Projected CAGR
34%
For the last 2 years the compound annual growth rate for Cuscal Ltd's net income is 5%. The projected CAGR for the next 3 years is 34%.
